Dr. Yu Shen joined BeiGene in September, 2023 as Vice President, Head of Biology.

Dr. Shen is a highly experienced leader in oncology drug discovery with more than 20 years in the industry, and he holds a Ph.D. from the University of North Carolina at Chapel Hill. Following postdoc training at Cold Spring Harbor Laboratory, Dr. Shen joined Abbott Laboratories/AbbVie in 2001, was inducted into Abbott’s esteemed Volwiler society in 2010, and advanced to Senior Research Fellow of ACoS (AbbVie’s equivalent of Volwiler society) in 2023. Throughout his tenure, Dr. Shen led multiple successful drug discovery programs, from target identification to clinical candidate selection and translational support.

Dr. Shen has in-depth expertise in cancer biology, including immuno-oncology, epigenetics, signal transduction, and tumor microenvironment. He brings extensive experience across diverse modalities from small molecules to antibody drug conjugates, nucleic acids, and more recently, PROTACs.